With more than 25 years of experience in management, corporate finance, and business development, Sæterøy is Managing Director of INVESTOR Corporate AS. He is a board member of NNN (chairman of NNN from 2010 – 2012) and Chairman of NNN member DiaGenic ASA from 2002 – 2010. Sæterøy is also a board member of Oslo Cancer Cluster and shareholder and board member of several life science companies in Norway. He has a Master of Science in Business from NHH in Bergen.
Erik Christensen, MD PhD
Former CEO at DiaGenic ASA for six years, Dr. Christensen previously worked for 10 years at Abbott Diagnostics, both as Medical Director Nordics and as Country Manager Norway. He is currently the chairman of Nansen Neuroscience Network and board member in Norwegian life science companies. His medical background is in clinical chemistry, and he holds a PhD in medical biochemistry from the University of Oslo.
Frank J. Swenson, PhD
At Pfizer Dr. Swenson was the Director of Precision Medicine Diagnostics and the research and commercial lead for Pfizer’s AD Diagnostic program. He initiated and led multiple Precision/ Personalized Medicine programs exploring and validating clinical sample assays as well as ophthalmic, and imaging biomarkers in Neurosciences and Infectious diseases. For 6 years he initiated several collaborative external pilot R&D studies to detect and monitor novel Early Alzheimer’s Disease biomarkers. Prior to Pfizer, he worked at several start up and large US Diagnostics companies for over 20 years in Research and Business development roles. He has successfully developed several worldwide regulatory approved medical devices/diagnostics. Dr. Swenson has a Ph.D. in Medical Sciences, MS in Immunology and a Doctorate in Optometry.